Inclusion Criteria:

          -  Female patients with stage II or III (cT1cN+ or ≥T2 any cN, cM0) breast cancer
             receiving neoadjuvant AC-T

          -  Measurable disease (breast and/or lymph nodes)

          -  HER2 negative core biopsy Age ≥18 years

          -  WHO performance status 0-2

          -  Adequate bone marrow function : white blood cells (WBCs) ≥3.0 x 109/l, neutrophils
             ≥1.5 x 109/l, platelets ≥100 x 109/l

          -  Adequate liver function: bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT
             and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase ≤5 x UNL

          -  Adequate renal function: the calculated creatinine clearance should be ≥50 mL/min

          -  Patients must be accessible for treatment and follow-up

          -  Written informed consent according to the local Ethics Committee requirements

          -  Willing to fill in quality of life questionnaires

          -  Able to read and write in Dutch

        Exclusion Criteria:

          -  History of breast cancer (invasive or non-invasive)

          -  Previous malignancy within 5 years, with exception of a history of a previous basal
             cell carcinoma of the skin or pre-invasive carcinoma of the cervix.

          -  Serious other diseases such as recent myocardial infarction, clinical signs of cardiac
             failure or clinically significant arrhythmias

          -  Diabetes Mellitus

          -  Body mass index (BMI) < 19 kg/m2

          -  Pregnancy or lactating

          -  Significant food allergies which would make the subject unable to consume the food
             provided (ex: nuts or soy)

          -  Any metabolic disorders that may affect gluconeogenesis or adaptation to short fasting
             periods.

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or sign meaningful informed consent